암연구소 소개
-
-
암연구소 소개
-
연구실 소개
연구실 소개
에피지네틱스 연구실
Laboratory of Epigenetics
본 연구실은 2000년 9월 설립되어 지난 20년 간 대장암, 위암, 간암 등한국인에서 호발하는 주요 암종의 후성유전학적 변화를 연구해 왔다. 연구실 구성원은 병리과 전문의/전공의와 전일제 연구원으로 구성되어 있으며, MethyLight assay, Pyrosequencing, droplet digital PCR, NGS 등 다양한 실험기법을 통하여 조직과 혈액, 체액 등 다양한 인체시료에서의 DNA메틸화 변화를 연구 중이다. CpG island hypermethylation과 LINE1, Alu 등 repetitive element의 hypomethylation에 초점을 맞추어 다단계 발암 과정에서의 DNA 메틸화 변화의 의의, 주요 암종의 분자아형(molecular subtype)에 따른 DNA 메틸화 변화의 임상병리학적 의의 및 예후 및 치료반응예측 바이오마커로서의 의의에 대한 연구를 지속적으로 수행 중이며, 연구분야를 확장하여 종양미세환경에 대한 정량적 분석 및 cell-free DNA를 이용한 암의 비침습적 진단 기법 등에 대한 연구도 활발하게 수행 중이다.
참여 연구원
연구내용
(1) Cancer Epigenetics
- 대장암, 위암, 간암 등의 한국인 호발암에서 일어나는 암특이적인 DNA 메틸화 변화 규명- 한국인 호발암의 다단계 발암 과정에서 일어나는 DNA 메틸화 변화의 시점에 대한 연구
- 유전체에서 LINE-1, Alu 등의 반복 요소(repetitive elements)의 저메틸화가 갖는 생물학적 및 임상적 의미, 바이오마커로서의 가치에 대한 연구
- 원발불명암에서 DNA 메틸화마커를 이용한 원발부위 예측패널 개발
(2) Tumor microenvironment
- 대장암, 위암의 주요 분자아형(molecular subtype)에 따른 종양미세환경(Tumor microenvironment)의 변화 및 바이오마커로서의 가치에 대한 연구
- Digital pathology 기반의 종양미세환경 정량적 분석 및 신규 바이오마커 발굴 연구
(3) Cell-free DNA
- 메틸화NGS, droplet digital PCR을 이용한 암의 비침습적 진단 연구
연구목표
후성유전학적 변화에 기반한 다양한 바이오마커 발굴 및 비침습적 암 조기 진단 방법 개발 등 translational research를 지속함과 더불어, 세포주, 오가노이드(organoid), 동물모델 등을 이용하여 암의 발생과 진행에 후성유전학적 변화가 미치는 영향을 규명하고자 한다.
연구성과
• Lee K, Song YS, Shin Y, Wen X, Kim Y, Cho NY, Bae JM, Kang GH. Intrahepatic cholangiocarcinomas with IDH1/2 mutation-associated hypermethylation at selective genes and their clinicopathological features. Sci Rep. 2020 sep 25;10(1):15820
• Jang BG, Kim HS, Bae JM, Kim WH, Kim HU, Kang GH. SMOC2, an intestinal stem cell marker, is an independent prognostic marker associated with better survival in colorectal cancers. Sci Rep. 2020 Sep 3;10(1):14591
• Lee JA, Yoo SY, Oh HJ, Jeong S, Cho NY, Kang GH, Kim JH. Differential immune microenvironmental features of microsatellite-unstable colorectal cancers according to Fusobacterium nucleatum status. Cancer Immunol Immunother. 2020 Jul 4 [Epub ahead of print]
• Kim Y, Rhee YY, Wen X, Cho NY, Bae JM, Kim WH, Kang GH. Combination of L1 methylation and tumor-infiltrating lymphocytes as prognostic marker in advanced gastric cancer. Gastric Cancer. 200 May;23(3):464-472
• Jang BG, Kim HS, Bae JM, Kim WH, Hyun CL, Kang GH. Expression profile and prognostic significance of EPHB3 in colorectal cancer. Biomolecules. 2020 Apr 13;10(4):602
• Yoo SY, Park HE, Kim JH, Wen X, Jeong S, Cho NY, Gwon HG, Kim K, Lee HS, Jeong SY, Park KJ, Han SW, Kim TY, Bae JM, Kang GH. Whole-slide image analysis reveals quantitative landscape of tumor-immune microenvironment in colorectal cancers. Clin Cancer Res. 2020 Feb 15:26(4):870-881
• Bae JM, Wen X, Kim TS, Kwak Y, Cho NY, Lee HS, Kang GH. Fibroblast growth factor receptor 1 (FGFR1) amplification detected by droplet digital polymerase chain reaction (ddPCR) is a prognostic factor in colorectal cancer. Cancer Res Treat. 2020 Jan:74-84
• Kim Y, Lee K, Jeong S, Wen X, Cho NY, Kang GH. DLEC1 methylation is associated with a better clinical outcome in patients with intrahepatic cholangiocarcinoma of the small duct type. Virchows Arch. 2019 Jul;475(1):49-58
• Oh HJ, Bae JM, Wen X, Jung S, Kim Y, Kim KJ, Cho NY, Kim JH, Han SW, Kim TY, Kang GH. P53 expression status is associated with cancer-specific survival in stage III and high-risk stage II colorectal cancer patients treated with oxaliplatin-based adjuvant chemotherapy. Br J Cancer. 2019 Apr;120(8):797-805
• Kim Y, Shin Y, Kang GH. Prognostic significance of CD103+ immune cells in solid tumor: a systematic review and meta-analysis. Sci Rep. 2019 Mar 7;9(1):3808
• Kim Y, Wen X, Jeong S, Cho NY, Kim WH, Kang GH. Combinatory low methylation statuses of SAT-α and L1 are associated with shortened survival time in patients with advanced gastric cancer. Gastric Cancer. 2019 Jan;22(1):37-47
• Kim Y, Wen X, Cho NY, Kang GH. Intratumoral immune cells expressing PD-1/PD-L1 and their prognostic impilcations in cancer: a meta-analysis. Int J Biol Markers. 2018 Nov 1;33(4):467-474
• Jang BG, Kim HS, Chang WY, Bae JM, Kim WH, Kang GH. Expression profile of LGR5 and its prognostic significance in colorectal cancer progression. Am J Pathol. 2018 Oct;188(10):2236-2250
• Bae JM, Kim JH, Park JH, Park HE, Cho NY, Kang GH. Clinicopathological and molecular implications of aberrant thyroid transcription factor-1 expression in colorectal carcinomas: an immunohistochemical analysis of 1319 cases using three different antibody clones. Histopathology. 2018 Feb;72(3):423-432
• Jang BG, Kim HS, Bae JM, Kim WH, Kim HU, Kang GH. SMOC2, an intestinal stem cell marker, is an independent prognostic marker associated with better survival in colorectal cancers. Sci Rep. 2020 Sep 3;10(1):14591
• Lee JA, Yoo SY, Oh HJ, Jeong S, Cho NY, Kang GH, Kim JH. Differential immune microenvironmental features of microsatellite-unstable colorectal cancers according to Fusobacterium nucleatum status. Cancer Immunol Immunother. 2020 Jul 4 [Epub ahead of print]
• Kim Y, Rhee YY, Wen X, Cho NY, Bae JM, Kim WH, Kang GH. Combination of L1 methylation and tumor-infiltrating lymphocytes as prognostic marker in advanced gastric cancer. Gastric Cancer. 200 May;23(3):464-472
• Jang BG, Kim HS, Bae JM, Kim WH, Hyun CL, Kang GH. Expression profile and prognostic significance of EPHB3 in colorectal cancer. Biomolecules. 2020 Apr 13;10(4):602
• Yoo SY, Park HE, Kim JH, Wen X, Jeong S, Cho NY, Gwon HG, Kim K, Lee HS, Jeong SY, Park KJ, Han SW, Kim TY, Bae JM, Kang GH. Whole-slide image analysis reveals quantitative landscape of tumor-immune microenvironment in colorectal cancers. Clin Cancer Res. 2020 Feb 15:26(4):870-881
• Bae JM, Wen X, Kim TS, Kwak Y, Cho NY, Lee HS, Kang GH. Fibroblast growth factor receptor 1 (FGFR1) amplification detected by droplet digital polymerase chain reaction (ddPCR) is a prognostic factor in colorectal cancer. Cancer Res Treat. 2020 Jan:74-84
• Kim Y, Lee K, Jeong S, Wen X, Cho NY, Kang GH. DLEC1 methylation is associated with a better clinical outcome in patients with intrahepatic cholangiocarcinoma of the small duct type. Virchows Arch. 2019 Jul;475(1):49-58
• Oh HJ, Bae JM, Wen X, Jung S, Kim Y, Kim KJ, Cho NY, Kim JH, Han SW, Kim TY, Kang GH. P53 expression status is associated with cancer-specific survival in stage III and high-risk stage II colorectal cancer patients treated with oxaliplatin-based adjuvant chemotherapy. Br J Cancer. 2019 Apr;120(8):797-805
• Kim Y, Shin Y, Kang GH. Prognostic significance of CD103+ immune cells in solid tumor: a systematic review and meta-analysis. Sci Rep. 2019 Mar 7;9(1):3808
• Kim Y, Wen X, Jeong S, Cho NY, Kim WH, Kang GH. Combinatory low methylation statuses of SAT-α and L1 are associated with shortened survival time in patients with advanced gastric cancer. Gastric Cancer. 2019 Jan;22(1):37-47
• Kim Y, Wen X, Cho NY, Kang GH. Intratumoral immune cells expressing PD-1/PD-L1 and their prognostic impilcations in cancer: a meta-analysis. Int J Biol Markers. 2018 Nov 1;33(4):467-474
• Jang BG, Kim HS, Chang WY, Bae JM, Kim WH, Kang GH. Expression profile of LGR5 and its prognostic significance in colorectal cancer progression. Am J Pathol. 2018 Oct;188(10):2236-2250
• Bae JM, Kim JH, Park JH, Park HE, Cho NY, Kang GH. Clinicopathological and molecular implications of aberrant thyroid transcription factor-1 expression in colorectal carcinomas: an immunohistochemical analysis of 1319 cases using three different antibody clones. Histopathology. 2018 Feb;72(3):423-432
구성원
| 성명 | 소속 | 직급 |
|---|---|---|
| 강경훈 | 서울대학교의과대학 병리학교실 | 교수 |
| 김정호 | 서울대학교병원 | 임상부교수 |
| 배정모 | 서울대학교병원 | 임상조교수 |
| 오현정 | 분당서울대학교병원 | 진료조교수 |
| 박혜은 | 서울특별시보라매병원 | 진료조교수 |
연구실사진
